萝莉乱伦

Xiaozhi Ren (任小峙) Ph.D. has held various roles in the biotechnology industry since 2010. In 2010, Xiaozhi held the role of Research Assistant II at The Jackson Laboratory. From 2011 to 2015, Xiaozhi was a Postdoctoral Fellow at King-Wai Yau Lab at The Johns Hopkins University School of Medicine, where they focused on Opsin biology and GPCR signaling pathway in rodent retina and other tissues, and designed and generated Johns Hopkins' first CRISPR based knock-in mouse model in early 2014. From 2015 to 2017, Xiaozhi was a Visiting Scientist at Michael Betenbaugh Lab at Johns Hopkins Whiting School of Engineering, where they mentored graduate students to engineer CHO cells to enhance antibody and secreted protein expression efficiency by CRISPR, and compared the effect of several chemicals on secreted protein production and post-translational modification in CHO cells. From 2017 to 2019, Xiaozhi was a Scientist at Cell Line Development Department at Sanofi, where they generated and evaluated stable cell lines for preclinical development programs, and led platform development projects on NEW CHO host cell line development/improvement/engineering, novel mammalian expression construct design, suspension cell culture medium optimization, CLD process establishment, and CLD SOP generation. In 2019, Xiaozhi held the roles of Director, CMC, Cell Line and Process Development, Associate Director, CMC, Cell Line and Process Development, and Senior Manager, CMC at Vedere Bio II, as well as Senior Process Development Scientist at Casebia Therapeutics, merged by CRISPR Therapeutics.

Xiaozhi Ren earned a Bachelor of Science (BS) in Biology from China Agricultural University in 2004, followed by a Doctor of Philosophy (Ph.D.) in Plant Molecular Biology from the same institution in 2010.